Search research articles
Contact Us
Filters
Showing results (1-10 of 77) with videos related to
Page
of 8
Sort By:
Nature Reviews. Drug Discovery
|
March 12, 2016
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
Oncoimmunology
|
June 28, 2012
The immuno-oncology framework: Enabling a new era of cancer therapy
Axel Hoos, Cedrik Britten
Expert Review of Vaccines
|
August 9, 2003
Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications
Axel Hoos, Daniel L Levey
Oncoimmunology
|
December 25, 2012
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
Axel Hoos, Sylvia Janetzki, Cedrik M Britten
Nature Reviews. Drug Discovery
|
April 9, 2021
Industrializing engineered autologous T cells as medicines for solid tumours
Cedrik M Britten, Aiman Shalabi, Axel Hoos
Nature Reviews. Drug Discovery
|
June 16, 2018
The promise and challenges of immune agonist antibody development in cancer
Patrick A Mayes, Kenneth W Hance, Axel Hoos
Nature Reviews. Drug Discovery
|
August 1, 2015
Big opportunities for small molecules in immuno-oncology
Jerry L Adams, James Smothers, Roopa Srinivasan, et al.
Nature Biotechnology
|
October 15, 2011
A methodological framework to enhance the clinical success of cancer immunotherapy
Axel Hoos, Cedrik M Britten, Christoph Huber, et al.
Surgical Oncology Clinics of North America
|
April 5, 2002
Randomized clinical trials in pancreatic cancer
Alexander Stojadinovic, Axel Hoos, Murray F Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology
Axel Hoos, Jedd D Wolchok, Rachel W Humphrey, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 77) with videos related to
Sort By:
Page
of 8
Nature Reviews. Drug Discovery
|
March 12, 2016
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
Oncoimmunology
|
June 28, 2012
The immuno-oncology framework: Enabling a new era of cancer therapy
Axel Hoos, Cedrik Britten
Expert Review of Vaccines
|
August 9, 2003
Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications
Axel Hoos, Daniel L Levey
Oncoimmunology
|
December 25, 2012
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring
Axel Hoos, Sylvia Janetzki, Cedrik M Britten
Nature Reviews. Drug Discovery
|
April 9, 2021
Industrializing engineered autologous T cells as medicines for solid tumours
Cedrik M Britten, Aiman Shalabi, Axel Hoos
Nature Reviews. Drug Discovery
|
June 16, 2018
The promise and challenges of immune agonist antibody development in cancer
Patrick A Mayes, Kenneth W Hance, Axel Hoos
Nature Reviews. Drug Discovery
|
August 1, 2015
Big opportunities for small molecules in immuno-oncology
Jerry L Adams, James Smothers, Roopa Srinivasan, et al.
Nature Biotechnology
|
October 15, 2011
A methodological framework to enhance the clinical success of cancer immunotherapy
Axel Hoos, Cedrik M Britten, Christoph Huber, et al.
Surgical Oncology Clinics of North America
|
April 5, 2002
Randomized clinical trials in pancreatic cancer
Alexander Stojadinovic, Axel Hoos, Murray F Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology
Axel Hoos, Jedd D Wolchok, Rachel W Humphrey, et al.
Page
of 8